Beam Therapeutics Inc
BEAM
查看详细走势图
26.520USD
+1.790+7.24%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.69B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.24%
5天
-3.98%
1月
-8.33%
6月
+48.49%
今年开始到现在
-4.33%
1年
-3.25%
查看详细走势图
TradingKey Beam Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Beam Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名70/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价46.52。中期看，股价处于上升通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Beam Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Beam Therapeutics Inc亮点
亮点风险
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
业绩增长期
公司处于发展阶段，最新年度总收入63.52M美元
利润高增长
公司净利润处于行业前列，最新年度总收入63.52M美元
估值合理
公司最新PE估值-6.01，处于3年历史合理位
机构加仓
最新机构持股103.60M股，环比增加0.02%
HACAX持仓
明星投资者HACAX持仓，最新持仓市值3.42K
分析师目标
根据
18
位分析师
买入
评级
46.520
目标均价
+72.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Beam Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Beam Therapeutics Inc简介
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
公司代码BEAM
公司Beam Therapeutics Inc
CEOEvans (John M)
网址https://beamtx.com/
相关品种
